Professional Documents
Culture Documents
(glimepirid)
Predavač:
Mjesto:
Datum:
MELPAMID® - INDIKACIJE
Početna
1mg/dan
doza
Maksimalna
6mg/dan
doza
MELPAMID® -EFIKASNOST
Sniženje vrijednosti
za 1,5 - 2% glikoziliranog
hemoglobina
(HbA1c)
http://www.diabetes.rs/dan011.htm
MELPAMID® - POSEBNA
UPOZORENJA
SmPC Melpamid
MELPAMID® - KLJUČNE
FARMAKOLOŠKE KARAKTERISTIKE
Clark: Cinical Trials with Glimepiride. Drugs Today 1998.; Roβkamp et al. Clinical Profile of the Novel Sulphonyluea glimepiride. Diabetes Res Clin Practice 1996.; Clinical profile od Glimepiride.
Diabetes Res Clin Practice 1995.; Sonnnenberg et al. Short –Tearm Comparasion of Once- Versus Twice- Daily Administration of Glimepiride in Patients With Non- InsulinDependent Diabetes
Mellitus. Ann Pharmacother 1997.
Kliničke studije
• Glimepirid podržava fiziološku inzulinsku regulaciju
Draeger KE et al. Long-Term Treatment of Type 2 Diabetic Patients with New Oral Antidiabetic Agent Glimepiride
A Double Blind Comparison wih Glibenclamide. Horm Metab Res 1996;28: 419-25
• Bolji sigurnosni profil glimepirida uz manji rizik nastajanja hipoglikemije,
koji se održava godinama!
Herrmann M et al. Glimepiride – Results of a non-interventional study. Diabetes Res Clin Pract 2000; 15 (suppl 1): 19 Feinböck C et al. Prospective multicentre trial comparing the efficacy of
and cpmpliance with Glimepiride versus Acarbose in the treatment of type 2 diabetes patients not controlled with diet alone. Data on file
Melpamid® (glimepirid) u kombinaciji sa inzulinom